Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22326226 | 0.91 | CRBN (0.47) | CRBNDDB1IKZF3TSHR | |
| SCHEMBL30767223 | 0.84 | CRBN (0.51) | CRBNDDB1IKZF3ALDH1A1CYP1A2 | |
| SCHEMBL27208328 | 0.83 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1 | |
| SCHEMBL27012609 | 0.83 | CRBN (0.49) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL21751118 | 0.79 | CRBN (0.55) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24233170 | 0.78 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL21751098 | 0.78 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL30241763 | 0.78 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23534466 | 0.78 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL21751104 | 0.78 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20220105188-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-04-07 | — | — | US | disclosed |
| WO-2020162725-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105188-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | EED, VHL, CUL1 | CRBN 4/4885DDB1 1206/4885IKZF3 360/4885 |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | CRBN 3597/4885DDB1 3120/4885IKZF3 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.